Transcriptional Targeting Approaches in Cardiac Gene Transfer Using AAV Vectors.
Lena C SchröderDerk FrankOliver J MüllerPublished in: Pathogens (Basel, Switzerland) (2023)
Cardiac-targeted transgene delivery offers new treatment opportunities for cardiovascular diseases, which massively contribute to global mortality. Restricted gene transfer to cardiac tissue might protect extracardiac organs from potential side-effects. This could be mediated by using cis-regulatory elements, including promoters and enhancers that act on the transcriptional level. Here, we discuss examples of tissue-specific promoters for targeted transcription in myocytes, cardiomyocytes, and chamber-specific cardiomyocytes. Some promotors are induced at pathological states, suggesting a potential use as "induction-by-disease switches" in gene therapy. Recent developments have resulted in the identification of novel enhancer-elements that could further pave the way for future refinement of transcriptional targeting, for example, into the cardiac conduction system.
Keyphrases
- gene therapy
- transcription factor
- left ventricular
- cancer therapy
- gene expression
- cardiovascular disease
- genome wide
- drug delivery
- type diabetes
- human health
- risk assessment
- risk factors
- atrial fibrillation
- dna methylation
- current status
- drug induced
- diabetic rats
- binding protein
- smoking cessation
- replacement therapy
- heat shock protein